Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Galluzzo

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Dermatology (Basel, Switzerland)|February 3, 2017
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 PatientsMarina Talamonti, Marco Galluzzo, Stella Servoli, et al.
Skin Health and Disease|February 5, 2024
Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case seriesMarco Galluzzo, Lorenzo Marcelli, Angela Fico, et al.
Molecular Diagnosis & Therapy|August 5, 2018
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast TherapyMarco Galluzzo, Simone D'Adamio, Elena Campione, et al.
Dermatologic Therapy|April 11, 2019
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literatureMarco Galluzzo, Simone D'Adamio, Miriam Teoli, et al.
JAAD Case Reports|September 11, 2023
Letter in response to the case report: "Recalcitrant generalized granuloma annulare treated successfully with dupilumab"Claudia Paganini, Marina Talamonti, Elena Campione, et al.
The British Journal of Dermatology|December 13, 2024
Comment on 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council': a case of rhabdomyolysis induced by upadacitinibEdoardo Mortato, Marina Talamonti, Claudia Paganini, et al.
Drug Design, Development and Therapy|September 19, 2017
New insight into the pathogenesis of nail psoriasis and overview of treatment strategiesAlessandra Ventura, Mauro Mazzeo, Roberta Gaziano, et al.
Expert Opinion on Pharmacotherapy|May 6, 2023
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasisMarco Galluzzo, Laura Vellucci, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|December 28, 2019
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasisMarco Galluzzo, Simone D'Adamio, Dionisio Silvaggio, et al.
Case Reports in Dermatology|October 29, 2013
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two casesRosita Saraceno, Marina Talamonti, Marco Galluzzo, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Dermatology (Basel, Switzerland)|February 3, 2017
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 PatientsMarina Talamonti, Marco Galluzzo, Stella Servoli, et al.
Skin Health and Disease|February 5, 2024
Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case seriesMarco Galluzzo, Lorenzo Marcelli, Angela Fico, et al.
Molecular Diagnosis & Therapy|August 5, 2018
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast TherapyMarco Galluzzo, Simone D'Adamio, Elena Campione, et al.
Dermatologic Therapy|April 11, 2019
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literatureMarco Galluzzo, Simone D'Adamio, Miriam Teoli, et al.
JAAD Case Reports|September 11, 2023
Letter in response to the case report: "Recalcitrant generalized granuloma annulare treated successfully with dupilumab"Claudia Paganini, Marina Talamonti, Elena Campione, et al.
The British Journal of Dermatology|December 13, 2024
Comment on 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council': a case of rhabdomyolysis induced by upadacitinibEdoardo Mortato, Marina Talamonti, Claudia Paganini, et al.
Drug Design, Development and Therapy|September 19, 2017
New insight into the pathogenesis of nail psoriasis and overview of treatment strategiesAlessandra Ventura, Mauro Mazzeo, Roberta Gaziano, et al.
Expert Opinion on Pharmacotherapy|May 6, 2023
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasisMarco Galluzzo, Laura Vellucci, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|December 28, 2019
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasisMarco Galluzzo, Simone D'Adamio, Dionisio Silvaggio, et al.
Case Reports in Dermatology|October 29, 2013
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two casesRosita Saraceno, Marina Talamonti, Marco Galluzzo, et al.
Pageof 12